Key result
Kidney transplant recipients with AMI are ~150% more likely to receive beta-blockers vs general patients.
Why the study?
Does kidney transplant status affect the likelihood of receiving cardioprotective medications after acute myocardial infarction compared to general patients?
Observational (n=52,213)
Yes
Does kidney transplant status affect the likelihood of receiving cardioprotective medications after acute myocardial infarction compared to general patients?
Odds Ratio: 2.5 (95% CI 1.7–3.68)
Absolute Event Rate: 83% vs 65.9%
p-value: p=<0.0001
Kidney transplant recipients are more likely to receive beta-blockers and statins after an acute myocardial infarction compared to matched general patients, indicating transplant status is not a barrier to secondary prevention.
No takes yet. Share an insight, caveat, or question.
Supports equitable post-AMI prescribing in transplant recipients; leaves open impact on outcomes and optimal regimens.
Lentine et al. (2011) conducted an observational in Acute myocardial infarction (n=52,213). Kidney transplant status vs. General patients was evaluated on Prescription fills for beta-blockers within 60 days after AMI (OR 2.50, 95% CI 1.70-3.68, p=<0.0001). Kidney transplant recipients with acute myocardial infarction were significantly more likely to receive beta-blockers (adjusted OR 2.50; 95% CI 1.70-3.68) and statins than general patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: